Medtronic PLC $MDT Shares Purchased by Capital World Investors

Capital World Investors boosted its holdings in Medtronic PLC (NYSE:MDT) by 19.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,578,946 shares of the medical technology company’s stock after purchasing an additional 1,061,167 shares during the quarter. Capital World Investors owned approximately 0.51% of Medtronic worth $626,579,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in MDT. Delos Wealth Advisors LLC purchased a new stake in shares of Medtronic during the second quarter valued at approximately $27,000. Corundum Trust Company INC acquired a new stake in shares of Medtronic during the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic in the 3rd quarter worth about $29,000. Steigerwald Gordon & Koch Inc. bought a new position in Medtronic in the 3rd quarter worth about $33,000. Finally, Tripletail Wealth Management LLC bought a new position in Medtronic in the 3rd quarter worth about $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on MDT shares. Morgan Stanley increased their price objective on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Needham & Company LLC reissued a “buy” rating and set a $120.00 price target on shares of Medtronic in a report on Tuesday. Sanford C. Bernstein lifted their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Finally, Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.74.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.26% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire Scientia Vascular for $550 million to bolster its neurovascular access and therapeutic portfolio — a strategic tuck‑in that expands “time‑is‑brain” capabilities and complements existing neurovascular product lines. Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
• Neutral Sentiment: Analyst coverage is active — a Benzinga deep dive summarizes 10 analyst ratings showing mixed views on MDT’s valuation and growth prospects; this keeps price target dispersion and investor debate elevated. Deep Dive Into Medtronic Stock: Analyst Perspectives (10 Ratings)
• Neutral Sentiment: Management commentary at the Barclays Healthcare Conference (transcript) reaffirmed strategy and longer‑term objectives; investors will be parsing any incremental detail on margin drivers, product cadence and the FY26 guide. Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Leadership change: Sean Haag named president of Medtronic’s ENT business — an operational move that matters for execution in ENT but is not expected to materially alter near‑term financials. Medtronic names Sean Haag president of ENT business
• Negative Sentiment: Competitive pressure from NeuroPace (NPCE) — recent coverage highlights product and reimbursement tailwinds for NeuroPace’s RNS system that could accelerate adoption in neuromodulation and pose longer‑term share/price pressure in adjacent markets. Investors view stronger competitor momentum as a headwind for Medtronic’s neuromodulation ambitions. NeuroPace’s Seizure ID and New Indication Could Expand RNS Demand
• Negative Sentiment: Macro/market volatility (rising VIX) is weighing on large‑cap medical device names, increasing downside risk from sector‑wide flows and multiple compression rather than company‑specific fundamentals. When Fear Spikes, These 5 Quiet, Overlooked Stocks Keep Delivering

Medtronic Trading Down 1.7%

Shares of Medtronic stock opened at $89.79 on Wednesday. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a market cap of $115.28 billion, a price-to-earnings ratio of 25.01, a price-to-earnings-growth ratio of 2.29 and a beta of 0.71. The business has a fifty day simple moving average of $98.45 and a 200-day simple moving average of $97.00. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period in the previous year, the company earned $1.38 earnings per share. Medtronic’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).